TIP_link_300x300.jpg
Dermatology Treatment Devices Market Size Set for Explosive Growth, With Projections Indicating $ 21.86 billion by 2031 | The Insight Partners
17. Dezember 2024 06:51 ET | The Insight Partners
US & Canada, Dec. 17, 2024 (GLOBE NEWSWIRE) -- According to a new comprehensive report from The Insight Partners, the Global Dermatology Treatment Devices Market is expected to reach US$ 21.86...
Palvella Logo.png
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
13. Dezember 2024 14:55 ET | Palvella Therapeutics Inc.
        Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for...
Inflation Reduction
Inflation Reduction Act Likely to Shape Specialty Prescribing Decisions in 2025, According to Spherix Global Insights
10. Dezember 2024 09:59 ET | Spherix Global Insights
EXTON, PA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- In 2022, the U.S. Congress enacted the Inflation Reduction Act (IRA), a landmark piece of legislation aimed at addressing various national priorities,...
logo.jpg.jpg
ViaDerma Announces Significant 2024 Achievements and International Expansion
10. Dezember 2024 08:00 ET | ViaDerma, Inc.
LOS ANGELES, Dec. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, proudly announces the completion of a...
AIVAVA BIOPHARMA COLOR.png
AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer
09. Dezember 2024 07:03 ET | AiViva Biopharma
AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma...
IMG_5356
Derm-Biome Pharmaceuticals adds Dr. Jerry Tan, internationally renowned expert in acne and acne scarring, to its Scientific Advisory Board
25. November 2024 10:00 ET | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company developing safe and highly effective topical treatments...
Olansky-Logo-Stacked-Final.png
Trent Renta Promoted to Chief Operating Officer at Olansky Dermatology & Aesthetics in Atlanta, Georgia
18. November 2024 16:44 ET | Olansky Dermatology & Aesthetics
Trent Renta promoted to Chief Operating Officer at Olansky Dermatology & Aesthetics in Atlanta, Georgia.
MJH-Life-Sciences-Logo (2).png
MJH Life Sciences® acquires Revolutionizing Atopic Dermatitis (RAD) Annual Meeting, expands leadership in dermatology education
18. November 2024 11:00 ET | MJH Shared Services, LLC
CRANBURY, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MJH Life Sciences®, a premier provider of health care events, media, and education, today announced the acquisition of the Revolutionizing Atopic...
Regeneron Logo.jpg
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
15. November 2024 00:59 ET | Regeneron Pharmaceuticals, Inc.
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by...
fortressbio1.jpg
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
14. November 2024 16:10 ET | Fortress Biotech, Inc.
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally...